Provided by Tiger Trade Technology Pte. Ltd.

CSPC PHARMA

8.770
-0.330-3.63%
Volume:150.35M
Turnover:1.32B
Market Cap:101.05B
PE:22.09
High:9.090
Open:8.900
Low:8.705
Close:9.100
52wk High:10.943
52wk Low:6.387
Shares:11.52B
HK Float Shares:11.52B
Volume Ratio:1.39
T/O Rate:1.30%
Dividend:0.34
Dividend Rate:3.84%
EPS(LYR):0.397
ROE:20.90%
ROA:10.70%
PB:2.30
PE(LYR):22.09
PS:2.76

Loading ...

CSPC Pharma's High-Activity Amylin Receptor Agonist Gets Green Light for Clinical Trials in China

Stock News
·
Aug 27

CSPC Pharma Secures NMPA Green Light for SYH2092, a Long-Acting Amylin Receptor Agonist Targeting Obesity and Type 2 Diabetes

Bulletin Express
·
Aug 27

CSPC Wins China Clinical Trial Approval for Syh2092 Amylin Agonist Injection

Reuters
·
Aug 27

CSPC Pharmaceutical - Pharma Obtains China Clinical Trial Approval for Syh2092 Injection

THOMSON REUTERS
·
Aug 27

CSPC Pharmaceutical - Highly Potent Amylin Receptor Agonist (Syh2092 Injection) Obtains Clinical Trial Approval in China

THOMSON REUTERS
·
Aug 27

CSPC PHARMA: DFZQ Disposes of Shares, Long Position Falls to 4.93%

HK Disclosure
·
Aug 27

CSPC Pharmaceutical Group (SEHK:1093) Rallies Following Strong H1 Results As Valuation Stays In Focus

Simply Wall St.
·
Aug 27

CSPC Pharma's Lung Cancer Candidate Meets Progression-Free Survival Primary Endpoint

MT Newswires Live
·
Aug 26

CSPC Pharma’s EGFR-Targeted ADC SYS6010 Achieves Primary PFS Endpoint in Phase III NSCLC Trial

Bulletin Express
·
Aug 26

CSPC Pharmaceutical Gains U.S. FDA Fast Track Status for Novel PD-1/IL-15 Fusion Protein in Hard-to-Treat Metastatic Colorectal Cancer

Bulletin Express
·
Aug 26

CSPC Pharma's SYS6090 (JMT108) Receives FDA Fast Track Designation for MSS/pMMR Metastatic Colorectal Cancer Treatment

Stock News
·
Aug 26

CSPC Pharma Says FDA Grants Fast Track Status to Sys6090 for MSS/pMMR Metastatic Colorectal Cancer

Reuters
·
Aug 26

CSPC Pharma's SYS6010 Achieves Primary Endpoint in Phase III Trial for EGFR-Mutant NSCLC Patients

Stock News
·
Aug 26

CSPC Pharmaceutical - Sys6090 (Jmt108) Granted Fast Track Designation by U.S. FDA for Mss/Pmmr Mcrc

THOMSON REUTERS
·
Aug 26

CSPC Pharmaceutical - Sys6010 Meets Primary Endpoint of Progression-Free Survival in Phase Iii Synstar-01 Study

THOMSON REUTERS
·
Aug 26

CSPC Pharmaceutical Group Stock Rallies 1.2% in Hong Kong, Underperforms Competitors

Dow Jones
·
Aug 26

Sihuan Pharmaceutical H1 Profit Jumps on Medical Aesthetics Unit Strength

Reuters
·
Aug 26

Movement Alert|CSPC PHARMA Rises 3.13% in Regular Trading, RSV Vaccine Receives FDA Clinical Trial Approval While Multiple Banks Raise Target Prices

Market Focus
·
Aug 26

CSPC Pharma secures U.S. FDA clearance for Phase I trial of second recombinant RSV vaccine SYS6057

Bulletin Express
·
Aug 25

CSPC Pharma's Recombinant RSV Vaccine Wins US Clinical Trial Clearance

Stock News
·
Aug 25